[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-population\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-population":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100552450","a-study-to-determine-safety-pharmakokinetics-and-efficacy-of-the-different-doses-of-vl-se-01-in-healthy-participants-100552450",false,"NCT06473246","A Study to Determine Safety, Pharmakokinetics and Efficacy of the Different Doses of VL-SE-01 in Healthy Participants.","A Randomized, Double-blind, Placebo Controlled, Parallel Study to Determine Safety, Pharmakokinetics and Efficacy of the Different Doses of VL-SE-01 in Healthy Participants.","Inclusion Criteria:\n\n* Male \\& female individuals must be 18 to 55 years of age inclusive, at the time of signing the informed consent.\n* Individuals who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.\n* Individual has a body weight of at least 50 kg (males) or 45 kg (females) and body mass index (BMI) within the range 18.5 to 29.9 kg\u002Fm2 (inclusive)\n* Individuals with a stressed lifestyle as assessed by PSS scores within 27- 40.\n* A male must agree to use contraception during the intervention period and for at least 7 days after the last dose of study intervention and refrain from donating sperm during this period.\n* A female is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:\n\n  1. Not a woman of childbearing potential (WOCBP)\n  2. OR agrees to use the contraceptive during the intervention period and for at least 90 days after the last dose of study intervention\n\nExclusion Criteria:\n\n* Individual has a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinology related, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention, or interfering with the interpretation of data.\n* Males who has a history of oligospermia, vasectomy and other sperm abnormalities.\n* Females who have irregularity or problems in menstrual cycles or diagnosed with polycystic ovarian syndrome.\n* Individuals with Type 1 and Type 2 Diabetes mellitus and on medication.\n* Individuals with SBP ≥ 160 mmHg and DBP ≥ 100 mmHg.\n* Individuals on anti-hypertensives.\n* History and\u002For current cases of chronic alcohol consumption or heavy drinkers as defined by:\n\n  1. For men, consuming more than 4 drinks on any day or more than 14 drinks\u002Fweek\n  2. For women, consuming more than 3 drinks on any day or more than 7 drinks\u002Fweek\n* Peri and post-menopausal women with no menstrual cycle in the last 6 months\n* Individuals with a history or actively under the influence of Hemp or CBD products by any means of administration\n* Individual has a known hypersensitivity to any components of the study medication or comparative drugs (and\u002For an investigational device) as stated in this protocol\n* Individual has a history of unexplained syncope or a family history of sudden death due to long QT syndrome\n* Individual with a history and\u002For currently diagnosed of cancer like lymphoma, leukaemia, or any malignancy.\n* Individual has past or intended use of prohibited medication or prescription medication including herbal medications within 2 weeks or 5 half-lives prior to dosing\n* Individuals have taken sleep medication within 2 weeks prior to screening\n* Individual has used hepatic enzyme-inducing drugs within 2 months prior to dosing\n* Individuals has alanine transaminase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) \\>1.5 times upper limit of normal (ULN)\n* Individual has current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)\n* Individual has any clinically relevant electrocardiogram (ECG) finding at the Screening Visit or at Baseline\n* Individual has a history of human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.",true,"ALL","18 Years","55 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","The present study is a randomized, placebo-controlled, parallel study. 250 participants will be screened, and considering a screening failure rate of 20%, approximately 200 participants will be randomized in a ratio of 1:1:1:1:1 to receive either different doses of VL-SE-01 or placebo and will be assigned a unique randomization code. Each group will have at least 30 participants (total 150 completers) after accounting for a dropout\u002Fwithdrawal rate of 25%. The intervention duration for all the study participants is 180 days.",[28],"Healthy Population","RECRUITING","2025-12-22",{"date":32,"type":33},"2025-12-30","ACTUAL",{"date":35,"type":33},"2025-02-20",{"date":37,"type":22},"2026-02-05",{"name":39,"class":40},"Vedic Lifesciences Pvt. Ltd.","INDUSTRY",6,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100588584","comparison-of-aerobic-training-and-circuit-training-in-healthy-children-100588584","NCT06943300","Comparison of Aerobic Training and Circuit Training in Healthy Children","Comparison of Aerobic Training and Circuit Training on Body Mass Index, Physical Fitness, and Quality of Life in Healthy Children","Inclusion Criteria:\n\n* ⦁ School Age Children from age 7-12 years\n\n  * Both Genders, Male and Female\n  * Healthy and fit children\n  * Interventions should be given inside the premises of school\n  * Children with normal range BMI: 13.3-24.1\n  * Children with presidential fitness score at or above the 85th percentile\n  * Children with Quality of Life score: minimum 50\n\nExclusion Criteria:\n\n* ⦁ Any Children havig any mental condition: Depession or Anxiety\n\n  * Visual, vestibular, or balance disorders in the preceding six months\n  * Children with any orthotic devices\n  * Children undertaking any previous aerobic or circuit training\n  * Refusal of any child or parent to participate","8 Years","12 Years",{"count":52,"type":22},28,[25],"Childhood obesity is a growing concern, with potential consequences for long-term health. The number of obese children has increased more than tenfold in the last forty years. Over the course of their lifetimes, more and more young people worldwide will be exposed to obesity, which will hasten the onset of type 2 diabetes, fatty liver, and cardiovascular problems. Promoting physical activity in children is crucial for maintaining a healthy weight and improving overall well-being. Less than 30% of kids and teenagers worldwide fulfill the recommended daily minimum of 60 minutes of moderate to intense physical activity. Since that most children and adolescents spend a significant amount of time traveling to and from school or attending school, schools may be the best places for interventions. This project will investigate the effectiveness of two common exercise approaches, aerobic training and circuit training, on body mass index (BMI), physical fitness, and quality of life in healthy children.\n\nA randomized controlled trial will be conducted, recruiting healthy children within a specific age range 8-12. This study will be conducted in the Leader's Lyceum School.Two experimental groups will be made. Participants will be randomly assigned to either an aerobic training group or a circuit training group. Non-probability convenient sampling technique will be used. The study will include the children from age 8 to 12, both genders, healthy children. Both programs will be implemented for a set duration of 12 weeks, with specific parameters regarding intensity, duration, and exercise types. The project will assess changes in BMI, physical fitness components (e.g., cardiovascular endurance, muscular strength, flexibility), and quality of life through validated measures, including Pediatric Quality of Life Generic Score 4.0 (PedsQL), Physical Fitness Test, Presidential Fitness test and BMI.",[28],[57,58,59,60,61,62],"Obesity","Physical Activity","Aerobic Training","Circuit Training","Body Mass Index","Quality of Life","NOT_YET_RECRUITING","2025-04-17",{"date":66,"type":33},"2025-04-24",{"date":68,"type":22},"2025-04-15",{"date":70,"type":22},"2025-07-14",{"name":72,"class":73},"Riphah International University","OTHER",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100561571","exploration-of-gender-differences-in-liver-aging-100561571","NCT06591897","Exploration of Gender Differences in Liver Aging","Inclusion Criteria:\n\n* Liver function indicators are in the normal reference range.\n* Liver imaging examination showed normal.\n\nExclusion Criteria:\n\n* Patients with previous liver-related diseases.\n* Subjects with important organ dysfunction \u002F failure or other serious diseases ( myocardial infarction, malignant tumor, severe neurological or psychiatric history, severe infection, coagulation dysfunction, etc. )\n* Moderate malnutrition ( BMI \\\u003C 17kg \u002F m2 ) and severe anemia ( Hb \\\u003C 60g \u002F L ).\n* Subjects and their families who disagreed with the study protocol.","80 Years",{"count":82,"type":22},18,"OBSERVATIONAL","The liver is an important metabolic organ in the body. It participates in central metabolic activities to maintain systemic homeostasis. It is also one of the most vulnerable organs in the process of individual aging. During aging, the volume, blood flow, metabolic capacity and regenerative capacity of the liver decrease. Liver function changes with age can lead to age-related systemic susceptibility diseases.\n\nTherefore, understanding the changes of metabolism and immune function in the process of liver aging and studying the regulation mechanism of liver aging will provide an important reference for understanding the causes of increased susceptibility to liver-related diseases in the elderly population.On the other hand, gender factors also affect organ function, leading to differences in human aging and disease outcomes.At present, the omics research on liver aging is mainly based on tissue-level transcription, protein or metabolomics, and most of the conclusions are focused on hepatocytes. However, for other cell types and microenvironment interactions, people know little about the aging changes at the cellular levelBased on the current research status, this study aims to explore the gender differences in the process of liver aging, using emerging technologies such as the combination of single-cell multi-omics and spatial localization, to reveal the factors driving liver aging from a gender perspective, and to promote the development of accurate interventions for aging and aging-related diseases.",[28],[87,88,89],"hepatocyte","liver function","sex differences","2024-10-06",{"date":92,"type":33},"2024-10-08",{"date":94,"type":33},"2024-09-27",{"date":96,"type":22},"2027-09-20",{"name":98,"class":73},"Second Affiliated Hospital, School of Medicine, Zhejiang University",1]